IP Library Granted Patent US 7,157,080
Granted Patent B2
US 7,157,080 · App. 10/752,464 · Granted Jan 2, 2007

Injectable hyaluronic acid derivative with pharmaceuticals/cells

Assignee: Fidia Advanced Biopolymers, SRL.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,157,080
App. No.
10/752,464
Granted
Jan 2, 2007
Kind
B2
Abstract

Disclosed is an injectable, biocompatible and biodegradable composition, comprising at least one hyaluronic acid benzyl ester or auto-cross-linked derivative, in combination with at least one mammalian cell and/or at least one pharmacologically or biologically active substance and/or micro-particles such as fibres, granules, microspheres or sponge fragments of a hyaluronic acid derivative.

Claims (10)

1. A method for the treatment of soft tissue comprising injecting at least one derivative of hyaluronic acid in the form of a gel in combination with a biologically or pharmacologically active component or cell into the tissue in need of treatment, wherein said hyaluronic acid derivative is selected from the group consisting of:

(a) benzyl ester hyaluronic acid wherein 50–75% of the carboxy groups are esterified with a benzyl radical; and

(b) an auto-cross-linked derivative of hyaluronic acid wherein 3–15% of the carboxyl groups of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.

2. The method according to claim 1 , wherein said benzyl ester is one wherein 50% of the carboxy groups are esterified with a benzyl radical.

3. The method according to claim 1 , wherein said mammalian cell is selected from the group consisting of chrondrocytes, osteocytes, fibroblasts, keratinocytes, adipocytes, muscle cells, nerve cells, cells from the peripheral nervous system, endothelial cells, hematopoietic cells, glandular cells, cells of the urethra, stem cells and genetically modified cells, both from adult and embryo, with the proviso that said mammalian cell is not a human embryonic cell.

4. The method according to claim 3 , wherein said cells are chondrocytes.

5. A method of treatment of cartilage damage which comprises injecting into the intra-articular space of a patient chondrocytes in combination with a hyaluronic acid derivative in the form of a gel, wherein said hyaluronic acid derivative is selected from the group consisting of:

(a) a benzyl ester of hyaluronic acid wherein 50–75% of the carboxy groups are esterified with a benzyl radical; and

(b) an auto-crosslinked derivative of hyaluronic acid wherein 3–15% of the carboxyl groups of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecules.

6. The method according to claim 5 , wherein said benzyl ester is one wherein 50% of the carboxy groups are esterified with a benzyl radical.

Assignments (1)
CHANGE OF NAME Recorded Nov 14, 2013
From: FIDIA ADVANCED BIOPOLYMERS S.R.L
To: ANIKA THERAPEUTICS S.R.L.
Reel/Frame 031600/0923 →
Priority Claims (1)
IT PD98A0298 · Dec 21, 1998 · national
Continuity (2)
Division 0988775700 · Jun 21, 2001
Related Publication 20040142465A1 · Jul 22, 2004